There’s good news for people with severe treatment-resistant depression: Esketamine is a groundbreaking therapy that can provide relief from major depression within hours.

3 days ago · Jan. 27, 2025 – After years of limited options, people with hard-to-treat depression finally have a new standalone treatment. The FDA’s latest approval of the nasal spray Spravato (esketamine ...

Jan 21, 2025 · SPRAVATO ® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression Following U.S. FDA Priority Review, approval is based on data demonstrating SPRAVATO® alone met its primary endpoint at 4 weeks and led to rapid and superior improvement in depressive symptoms compared to placebo as early as 24 hours1 SPRAVATO® alone showed a rapid ...

2 days ago · Intranasal esketamine has been approved as an adjunctive therapy for treatment-resistant major depressive disorder with acute suicidal ideation and behavior. The authors conducted a systematic review and meta-analysis of the available data on its efficacy against depression and suicidality as well as its side effects.

Esketamine nasal spray is recommended for adults diagnosed with major depressive disorder (MDD) who did not respond to at least two antidepressants, and who currently have a major depressive episode of moderate or severe intensity (1, 6).

Jan 22, 2025 · In a significant step forward for mental health care, the U.S. Food and Drug Administration (FDA) has expanded its approval of Spravato (esketamine) nasal spray. Initially approved in 2019 for treatment-resistant depression, Spravato is now cleared for use as a standalone treatment for major depressive disorder (MDD).

Sep 1, 2024 · Esketamine nasal spray is used together with an antidepressant taken by mouth, to treat patients with depression who have previously received at least 2 antidepressant treatments that did not work well (treatment-resistant depression).

Jul 12, 2019 · Esketamine helps create more of those connections between the brain cells. That may ease symptoms of depression. Esketamine also has been shown to decrease suicidal thoughts and tendencies more effectively and more quickly than other antidepressants.

The overall findings demonstrated that treatment with intranasal esketamine in combination with a new oral antidepressant was more effective than placebo plus an oral antidepressant, and associated with a rapid reduction of depressive symptoms and delayed time to relapse from symptoms of depression. 76, 78 Consistent with the short-term ...

Oct 4, 2023 · In this trial involving patients with treatment-resistant depression, esketamine nasal spray was superior to the comparator, extended-release quetiapine, a commonly used antipsychotic...